Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer. - Wikidata - awgldk - TriplyDB

Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.

Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.

http://www.wikidata.org/entity/Q37581685

about

Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.

P2860

Q47426456-A905B585-0719-4EF5-B393-E42192256D2C

P2860

Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.

http://www.wikidata.org/entity/Q37581685

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Epidermal growth factor recept ...... growth factor in lung cancer.

@en

Epidermal growth factor recept ...... growth factor in lung cancer.

@nl

type

label

Epidermal growth factor recept ...... growth factor in lung cancer.

@en

Epidermal growth factor recept ...... growth factor in lung cancer.

@nl

prefLabel

Epidermal growth factor recept ...... growth factor in lung cancer.

@en

Epidermal growth factor recept ...... growth factor in lung cancer.

@nl

P1433

Q37581685-8D006FED-4D4F-479A-87D6-FF5A1601A1EF

P1476

Q37581685-FBC46060-6CD5-4C9B-98E8-F6D9EFE1396E

P2093

Q37581685-17BF26B5-952B-4CAE-A748-AF1E6E334C65

Q37581685-18BC20A6-E610-4793-AB41-214F11D016A4

Q37581685-8CB5AA43-3EF4-494D-83F6-2722B080818E

Q37581685-97716295-1932-465D-9562-F95FC1B7189B

Q37581685-A9D3F3F9-0FB8-4A1C-9B6D-4413648E8CE9

Q37581685-E1B33458-716D-4D14-890B-C301248317E9

Q37581685-FF94C7AC-A00D-47DD-B829-91A5208D6AD8

P2860

Q37581685-02884D4D-F68D-411F-A4E4-E3482F2EB8F2

Q37581685-0FC96996-5E89-43FA-BE92-DEA23EF8A476

Q37581685-1EDEF054-16AE-4713-8AB0-1D8C0D10960D

Q37581685-446894BB-C2AC-4B73-A45A-4557D707BCFF

Q37581685-4E0EB735-7A22-4106-A1FF-222FF515A681

Q37581685-5D8942F0-7958-49B4-AEC8-C4F6773D7169

Q37581685-72676AC7-05A9-4648-ACB6-6AA906FBC458

Q37581685-737E2294-B2BF-4999-9C24-067B2083A945

Q37581685-7DA7849E-333C-4E6C-903D-7B2E7BE2FDC2

Q37581685-85BB190C-79EE-4B7F-B9D1-0A2C99236F99

P304

Q37581685-7D1AF7A5-3AE5-4832-9946-28EE965AB142

P31

Q37581685-83A0EDCF-5D82-47DB-84EE-ACC0451428ED

P356

Q37581685-8DEEEA2B-A216-41C0-8C29-24CF4853E587

P433

Q37581685-B16F768B-CC75-4003-B52D-08D01FFD9A4C

P478

Q37581685-E2BDC070-C404-423B-AF85-87E147892EEA

P50

Q37581685-DB685569-6B1A-40F0-B3D4-AE4A9501C1DB

P577

Q37581685-3B23ABD8-5930-4EEE-A35C-B3047E7936BB

P698

Q37581685-E9D0ED91-813E-4404-9B67-0CC0421EEAEC

P921

Q37581685-4A28291A-A61A-43B7-8A05-BCC8CCA1746C

P932

Q37581685-F3C1A550-949A-40DA-8EE5-E112694ED60C

P356

P1433

Oncology Letters

P1476

Epidermal growth factor recept ...... l growth factor in lung cancer

@en

P2093

I-Chuan Chen

http://www.w3.org/2001/XMLSchema#string

Jr-Hau Lung

http://www.w3.org/2001/XMLSchema#string

Ming-Szu Hung

http://www.w3.org/2001/XMLSchema#string

Paul-Yann Lin

http://www.w3.org/2001/XMLSchema#string

Ya-Chin Li

http://www.w3.org/2001/XMLSchema#string

Ying-Huang Tsai

http://www.w3.org/2001/XMLSchema#string

Yu-Ching Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.

Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

P304

4598-4604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2016.5287

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28101216

http://www.w3.org/2001/XMLSchema#string

P921

P932

5228119

http://www.w3.org/2001/XMLSchema#string